Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All convalescent plasma..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchConvalescent PlasmaConv. Plasma (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   

Efficacy of convalescent plasma for treatment of COVID-19 in Uganda

Kirenga et al., BMJ Open Respiratory Research, doi:10.1136/bmjresp-2021-001017, COVIDIT, NCT04542941
Aug 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality -21% Improvement Relative Risk Progression 9% Recovery time 0% no CI Time to viral- -50% Conv. Plasma  COVIDIT  LATE TREATMENT  RCT Is late treatment with convalescent plasma beneficial for COVID-19? RCT 136 patients in Uganda (June - December 2020) Slower viral clearance with convalescent plasma (not stat. sig., p=0.2) c19early.org Kirenga et al., BMJ Open Respiratory R.., Aug 2021 Favorsconv. plasma Favorscontrol 0 0.5 1 1.5 2+
RCT 136 hospitalized COVID-19 patients in Uganda, showing no significant benefit with convalescent plasma treatment.
risk of death, 21.4% higher, RR 1.21, p = 0.80, treatment 10 of 69 (14.5%), control 8 of 67 (11.9%).
risk of progression, 9.1% lower, RR 0.91, p = 1.00, treatment 9 of 41 (22.0%), control 7 of 29 (24.1%), NNT 46.
recovery time, no change, relative time 1.00, p = 0.77, treatment 59, control 61.
time to viral-, 50.0% higher, relative time 1.50, p = 0.20, treatment 67, control 67.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kirenga et al., 9 Aug 2021, Randomized Controlled Trial, Uganda, peer-reviewed, median age 50.0, 30 authors, study period 16 June, 2020 - 31 December, 2020, average treatment delay 7.0 days, trial NCT04542941 (history) (COVIDIT). Contact: brucekirenga@yahoo.co.uk.
This PaperConv. PlasmaAll
Efficacy of convalescent plasma for treatment of COVID-19 in Uganda
Dr Bruce Kirenga, Pauline Byakika-Kibwika, Winters Muttamba, Alex Kayongo, Namakula Olive Loryndah, Levicatus Mugenyi, Noah Kiwanuka, John Lusiba, Angella Atukunda, Raymond Mugume, Francis Ssali, Henry Ddungu, Winceslaus Katagira, Rogers Sekibira, Cissy Kityo, Dorothy Kyeyune, Susan Acana, Hellen Aanyu-Tukamuhebwa, Wilberforce Kabweru, Fred Nakwagala, Bernard Sentalo Bagaya, Ivan Kimuli, Rebecca Nantanda, Esther Buregyeya, Baterana Byarugaba, Charles Olaro, Henry G Mwebesa, Moses Lutaakome Joloba, Trishul Siddharthan, William Bazeyo
BMJ Open Respiratory Research, doi:10.1136/bmjresp-2021-001017
Rationale Convalescent plasma (CCP) has been studied as a potential therapy for COVID-19, but data on its efficacy in Africa are limited. Objective In this trial we set out to determine the efficacy of CCP for treatment of COVID-19 in Uganda. Measurements Patients with a positive SARS-CoV-2 reverse transcriptase (RT)-PCR test irrespective of disease severity were hospitalised and randomised to receive either COVID-19 CCP plus standard of care (SOC) or SOC alone. The primary outcome was time to viral clearance, defined as having two consecutive RT-PCR-negative tests by day 28. Secondary outcomes included time to symptom resolution, clinical status on the modified WHO Ordinal Clinical Scale (≥1-point increase), progression to severe/ critical condition (defined as oxygen saturation <93% or needing oxygen), mortality and safety. Main results A total of 136 patients were randomised, 69 to CCP+SOC and 67 to SOC only. The median age was 50 years (IQR: 38.5-62.0), 71.3% were male and the median duration of symptom was 7 days (IQR=4-8). Time to viral clearance was not different between the CCP+SOC and SOC arms (median of 6 days (IQR=4-11) vs 4 (IQR=4-6), p=0.196). There were no statistically significant differences in secondary outcomes in CCP+SOC versus SOC: time to symptom resolution (median=7 (IQR=5-7) vs 7 (IQR=5-10) days, p=0.450), disease progression (9 (22.0%) vs 7 (24.0%) patients, p=0.830) and mortality (10 (14.5%) vs 8 (11.9%) deaths, p=0.476). Conclusion In this African trial, CCP therapy did not result in beneficial virological or clinical improvements. Further trials are needed to determine subgroups of patients who may benefit from CCP in Africa. Trial registration number NCT04542941.
Competing interests None declared. Patient consent for publication Not required. Ethics approval Trial ethical and regulatory approvals were obtained from the Mulago Hospital Research and Ethics Committee (MHREC) under reference number MHREC 1902, the National Drug Authority, and the Uganda National Council for Science and Technology under reference number HS816 ES. This study was conducted according to the principles of the Declaration of Helsinki and Good Clinical Practice. Provenance and peer review Not commissioned; externally peer reviewed. Data availability statement Data are available upon reasonable request. Data collected for this trial, including de-identified individual participant data and a data dictionary defining each field in the set, will be made available to others upon reasonable request. Additional, related documents including study protocol, statistical analysis plan and informed consent forms will be made available upon reasonable request. A formal request should be sent via email to the clinical trial principal investigator Dr Bruce Kirenga at brucekirenga@ yahoo. com. After approval of a proposal by an institutional research board with a signed data access agreement, data will be made available. Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not..
References
Abolghasemi, Eshghi, Cheraghali, Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study, Transfus Apher Sci, doi:10.1016/j.transci.2020.102875
Agarwal, Mukherjee, Kumar, Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial), BMJ, doi:10.1136/bmj.m3939
Borghesi, Maroldi, Rjlrm, COVID-19 outbreak in Italy: experimental chest X-ray scoring system for quantifying and monitoring disease progression, Radiol Med, doi:10.1007/s11547-020-01200-3
Budhiraja, Dewan, Aggarwal, Effectiveness of convalescent plasma in Indian patients with COVID-19, Blood Cells Mol Dis, doi:10.1016/j.bcmd.2021.102548
Callaway, Ledford, How to redesign COVID vaccines so they protect against variants, Nature, doi:10.1038/d41586-021-00241-6
Cheng, Wong, Soo, Use of convalescent plasma therapy in SARS patients in Hong Kong, Eur J Clin Microbiol Infect Dis, doi:10.1007/s10096-004-1271-9
Dai, Gu, Hao, Potential benefits, mechanisms, and uncertainties of convalescent plasma therapy for COVID-19, Blood Sci, doi:10.1097/BS9.0000000000000047
Flyak, Ilinykh, Murin, Mechanism of human antibodymediated neutralization of Marburg virus, Cell, doi:10.1016/j.cell.2015.01.031
Garraud, Heshmati, Pozzetto, Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow, Transfus Clin Biol, doi:10.1016/j.tracli.2015.12.003
Gharbharan, Jordans, Geurtsvankessel, Convalescent plasma for COVID-19. A randomized clinical trial, Medrxiv, doi:10.1101/2020.07.01.20139857
Gharbharan, Jordans, Geurtsvankessel, Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection, Nat Commun, doi:10.1038/s41467-021-23469-2
Horby, Pessoa-Amorim, Peto, Tocilizumab in patients admitted to hospital with COVID-19 (recovery): preliminary results of a randomised, controlled, open-label, platform trial, doi:10.1101/2021.02.11.21249258
Joyner, Senefeld, Klassen, Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience, medRxiv, doi:10.1101/2020.08.12.20169359
Ko, Joo, Park, Neutralizing antibody production in asymptomatic and mild COVID-19 patients, in comparison with pneumonic COVID-19 patients, J Clin Med, doi:10.3390/jcm9072268
Li, Zhang, Hu, Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial, JAMA, doi:10.1001/jama.2020.10044
Li, Zhang, Hu, Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and lifethreatening COVID-19, JAMA, doi:10.1001/jama.2020.10044
Libster, Marc, Wappner, Early high-titer plasma therapy to prevent severe Covid-19 in older adults
Liu, Fan, Li, Antibody-dependent-cellular-cytotoxicityinducing antibodies significantly affect the post-exposure treatment of Ebola virus infection, Sci Rep, doi:10.1038/srep45552
Liu, Morgenstern, Kelly, The impact of nonpharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories, BMC Med, doi:10.1186/s12916-020-01872-8
Lu, Murakowski, Bournazos, Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo, Science, doi:10.1126/science.aaf1279
Mahase, Covid-19: what new variants are emerging and how are they being investigated?, BMJ, doi:10.1136/bmj.n158
Medicine, Interleukin-6 receptor antagonists in critically ill patients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2100433
Muttamba, Lusiba, Namakula, Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda
Muttamba, Lusiba, Namakula, Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda, PLoS One, doi:10.1371/journal.pone.0252306
Nio, The COVID-19 treatment guidelines panel's statement on the emergency use authorization of convalescent plasma for the treatment of COVID-19
Olivares-Gazca, Priesca-Marín, Ojeda-Laguna, Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: a pilot study, RIC, doi:10.24875/RIC.20000237
Rajendran, Krishnasamy, Rangarajan, Convalescent plasma transfusion for the treatment of COVID-19: systematic review, J Med Virol, doi:10.1002/jmv.25961
Rambar, Convalescent serum and pooled plasma in communicable diseases, U S Nav Med Bull
Rcgjnejo, Dexamethasone in hospitalized patients with Covid-19-preliminary report
Simonovich, Pratx, Scibona, A randomized trial of convalescent plasma in Covid-19 severe pneumonia, N Engl J Med, doi:10.1056/NEJMoa2031304
Wang, Zhang, Du, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, doi:10.1016/S0140-6736(20)31022-9
Winkler, Koepsell, Sajcoih, The use of convalescent plasma to treat emerging infectious diseases, Curr Opin Hematol, doi:10.1097/MOH.0000000000000191
Xu, Han, Li, Effective treatment of severe COVID-19 patients with tocilizumab, Proc Natl Acad Sci U S A, doi:10.1073/pnas.2005615117
{ 'indexed': {'date-parts': [[2023, 4, 8]], 'date-time': '2023-04-08T22:47:07Z', 'timestamp': 1680994027187}, 'reference-count': 36, 'publisher': 'BMJ', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2021, 8, 8]], 'date-time': '2021-08-08T00:00:00Z', 'timestamp': 1628380800000}, 'content-version': 'unspecified', 'delay-in-days': 7, 'URL': 'http://creativecommons.org/licenses/by-nc/4.0/'}], 'funder': [{'name': 'Government of Uganda', 'award': ['MakRIF']}], 'content-domain': {'domain': ['bmj.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2021, 8]]}, 'abstract': '<jats:sec><jats:title>Rationale</jats:title><jats:p>Convalescent plasma (CCP) has been ' 'studied as a potential therapy for COVID-19, but data on its efficacy in Africa are ' 'limited.</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>In this trial ' 'we set out to determine the efficacy of CCP for treatment of COVID-19 in ' 'Uganda.</jats:p></jats:sec><jats:sec><jats:title>Measurements</jats:title><jats:p>Patients ' 'with a positive SARS-CoV-2 reverse transcriptase (RT)-PCR test irrespective of disease ' 'severity were hospitalised and randomised to receive either COVID-19 CCP plus standard of ' 'care (SOC) or SOC alone. The primary outcome was time to viral clearance, defined as having ' 'two consecutive RT-PCR-negative tests by day 28. Secondary outcomes included time to symptom ' 'resolution, clinical status on the modified WHO Ordinal Clinical Scale (≥1-point increase), ' 'progression to severe/critical condition (defined as oxygen saturation &lt;93%\u2009or ' 'needing oxygen), mortality and safety.</jats:p></jats:sec><jats:sec><jats:title>Main ' 'results</jats:title><jats:p>A total of 136 patients were randomised, 69 to CCP+SOC\u2009and ' '67 to SOC only. The median age was 50 years (IQR: 38.5–62.0), 71.3% were male and the median ' 'duration of symptom was 7\u2009days (IQR=4–8). Time to viral clearance was not different ' 'between the CCP+SOC\u2009and SOC arms (median of 6\u2009days (IQR=4–11) vs 4 (IQR=4–6), ' 'p=0.196). There were no statistically significant differences in secondary outcomes in ' 'CCP+SOC\u2009versus SOC: time to symptom resolution (median=7 (IQR=5–7) vs 7 (IQR=5–10) days, ' 'p=0.450), disease progression (9 (22.0%) vs 7 (24.0%) patients, p=0.830) and mortality (10 ' '(14.5%) vs 8 (11.9%) deaths, ' 'p=0.476).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>In this ' 'African trial, CCP therapy did not result in beneficial virological or clinical improvements. ' 'Further trials are needed to determine subgroups of patients who may benefit from CCP in ' 'Africa.</jats:p><jats:p><jats:bold>Trial registration number</jats:bold><jats:ext-link ' 'xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="clintrialgov" ' 'xlink:href="NCT04542941">NCT04542941</jats:ext-link>.</jats:p></jats:sec>', 'DOI': '10.1136/bmjresp-2021-001017', 'type': 'journal-article', 'created': {'date-parts': [[2021, 8, 10]], 'date-time': '2021-08-10T03:11:10Z', 'timestamp': 1628565070000}, 'page': 'e001017', 'update-policy': 'http://dx.doi.org/10.1136/crossmarkpolicy', 'source': 'Crossref', 'is-referenced-by-count': 22, 'title': 'Efficacy of convalescent plasma for treatment of COVID-19 in Uganda', 'prefix': '10.1136', 'volume': '8', 'clinical-trial-number': [ { 'clinical-trial-number': 'nct04542941', 'registry': '10.18810/clinical-trials-gov'}], 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-2023-2840', 'authenticated-orcid': False, 'given': 'Bruce', 'family': 'Kirenga', 'sequence': 'first', 'affiliation': []}, {'given': 'Pauline', 'family': 'Byakika-Kibwika', 'sequence': 'additional', 'affiliation': []}, {'given': 'Winters', 'family': 'Muttamba', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alex', 'family': 'Kayongo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Namakula Olive', 'family': 'Loryndah', 'sequence': 'additional', 'affiliation': []}, {'given': 'Levicatus', 'family': 'Mugenyi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Noah', 'family': 'Kiwanuka', 'sequence': 'additional', 'affiliation': []}, {'given': 'John', 'family': 'Lusiba', 'sequence': 'additional', 'affiliation': []}, {'given': 'Angella', 'family': 'Atukunda', 'sequence': 'additional', 'affiliation': []}, {'given': 'Raymond', 'family': 'Mugume', 'sequence': 'additional', 'affiliation': []}, {'given': 'Francis', 'family': 'Ssali', 'sequence': 'additional', 'affiliation': []}, {'given': 'Henry', 'family': 'Ddungu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Winceslaus', 'family': 'Katagira', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rogers', 'family': 'Sekibira', 'sequence': 'additional', 'affiliation': []}, {'given': 'Cissy', 'family': 'Kityo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Dorothy', 'family': 'Kyeyune', 'sequence': 'additional', 'affiliation': []}, {'given': 'Susan', 'family': 'Acana', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hellen', 'family': 'Aanyu-Tukamuhebwa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Wilberforce', 'family': 'Kabweru', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fred', 'family': 'Nakwagala', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bernard Sentalo', 'family': 'Bagaya', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ivan', 'family': 'Kimuli', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rebecca', 'family': 'Nantanda', 'sequence': 'additional', 'affiliation': []}, {'given': 'Esther', 'family': 'Buregyeya', 'sequence': 'additional', 'affiliation': []}, {'given': 'Baterana', 'family': 'Byarugaba', 'sequence': 'additional', 'affiliation': []}, {'given': 'Charles', 'family': 'Olaro', 'sequence': 'additional', 'affiliation': []}, {'given': 'Henry', 'family': 'Mwebesa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Moses Lutaakome', 'family': 'Joloba', 'sequence': 'additional', 'affiliation': []}, {'given': 'Trishul', 'family': 'Siddharthan', 'sequence': 'additional', 'affiliation': []}, {'given': 'William', 'family': 'Bazeyo', 'sequence': 'additional', 'affiliation': []}], 'member': '239', 'published-online': {'date-parts': [[2021, 8, 9]]}, 'reference': [ { 'key': '2022063000100525000_8.1.e001017.1', 'unstructured': 'Uganda Ministry of health Covid 19 pandemic. Available: ' 'https://www.health.go.ug/covid/about-corona-virus/ [Accessed 20 Mar ' '2021].'}, { 'key': '2022063000100525000_8.1.e001017.2', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s12916-021-01924-7'}, { 'key': '2022063000100525000_8.1.e001017.3', 'doi-asserted-by': 'crossref', 'first-page': '15', 'DOI': '10.1038/d41586-021-00241-6', 'article-title': 'How to redesign COVID vaccines so they protect against variants', 'volume': '590', 'author': 'Callaway', 'year': '2021', 'journal-title': 'Nature'}, { 'key': '2022063000100525000_8.1.e001017.4', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.n158'}, { 'key': '2022063000100525000_8.1.e001017.5', 'unstructured': 'Government of Uganda . National Guidelines for Management of Covid-19 - ' 'Ministry of Health. Available: ' 'https://www.health.go.ug/cause/national-guidelines-for-management-of-covid-19/ ' '[Accessed 10 Mar 2021].'}, { 'key': '2022063000100525000_8.1.e001017.6', 'doi-asserted-by': 'publisher', 'DOI': '10.1073/pnas.2005615117'}, { 'key': '2022063000100525000_8.1.e001017.7', 'doi-asserted-by': 'crossref', 'unstructured': 'Medicine R-CIJNEJo . Interleukin-6 receptor antagonists in critically ' 'ill patients with Covid-19. N Engl J Med 2021.doi:10.1056/NEJMoa2100433', 'DOI': '10.1056/NEJMoa2100433'}, { 'key': '2022063000100525000_8.1.e001017.8', 'doi-asserted-by': 'crossref', 'unstructured': 'Horby PW , Pessoa-Amorim G , Peto L . Tocilizumab in patients admitted ' 'to hospital with COVID-19 (recovery): preliminary results of a ' 'randomised, controlled, open-label, platform trial. Medrxiv ' '2021.doi:10.1101/2021.02.11.21249258', 'DOI': '10.1101/2021.02.11.21249258'}, { 'key': '2022063000100525000_8.1.e001017.9', 'unstructured': 'NIo H . The COVID-19 treatment guidelines panel’s statement on the ' 'emergency use authorization of convalescent plasma for the treatment of ' 'COVID-19, 2020.'}, { 'key': '2022063000100525000_8.1.e001017.10', 'unstructured': 'Medicine RCGJNEJo . Dexamethasone in hospitalized patients with ' 'Covid-19—preliminary report, 2020.'}, { 'key': '2022063000100525000_8.1.e001017.11', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)31022-9'}, { 'key': '2022063000100525000_8.1.e001017.12', 'first-page': '93', 'article-title': 'Convalescent serum and pooled plasma in communicable diseases', 'volume': '46', 'author': 'RAMBAR', 'year': '1946', 'journal-title': 'U S Nav Med Bull'}, { 'key': '2022063000100525000_8.1.e001017.13', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.tracli.2015.12.003'}, { 'key': '2022063000100525000_8.1.e001017.14', 'doi-asserted-by': 'publisher', 'DOI': '10.1097/moh.0000000000000191'}, { 'key': '2022063000100525000_8.1.e001017.15', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.bcmd.2021.102548'}, { 'key': '2022063000100525000_8.1.e001017.16', 'doi-asserted-by': 'crossref', 'first-page': '159', 'DOI': '10.24875/RIC.20000237', 'article-title': 'Infusion of convalescent plasma is associated with clinical improvement ' 'in critically ill patients with COVID-19: a pilot study', 'volume': '72', 'author': 'Olivares-Gazca', 'year': '2020', 'journal-title': 'RIC'}, { 'key': '2022063000100525000_8.1.e001017.17', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2031304'}, { 'key': '2022063000100525000_8.1.e001017.18', 'unstructured': 'Libster R , Pérez Marc G , Wappner D . Early high-titer plasma therapy ' 'to prevent severe Covid-19 in older adults 2021.'}, { 'key': '2022063000100525000_8.1.e001017.19', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.1004'}, { 'key': '2022063000100525000_8.1.e001017.20', 'article-title': 'Effect of convalescent plasma on mortality among hospitalized patients ' 'with COVID-19: initial three-month experience', 'author': 'Joyner', 'year': '2020', 'journal-title': 'medRxiv'}, { 'key': '2022063000100525000_8.1.e001017.21', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41467-020-20241-w'}, { 'key': '2022063000100525000_8.1.e001017.22', 'doi-asserted-by': 'crossref', 'first-page': 'm3939', 'DOI': '10.1136/bmj.m3939', 'article-title': 'Convalescent plasma in the management of moderate covid-19 in adults in ' 'India: open label phase II multicentre randomised controlled trial ' '(PLACID trial)', 'volume': '151', 'author': 'Agarwal', 'year': '2020', 'journal-title': 'BMJ'}, { 'key': '2022063000100525000_8.1.e001017.23', 'doi-asserted-by': 'crossref', 'first-page': '71', 'DOI': '10.1097/BS9.0000000000000047', 'article-title': 'Potential benefits, mechanisms, and uncertainties of convalescent ' 'plasma therapy for COVID-19', 'volume': '2', 'author': 'Dai', 'year': '2020', 'journal-title': 'Blood Sci'}, { 'key': '2022063000100525000_8.1.e001017.24', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cell.2015.01.031'}, { 'key': '2022063000100525000_8.1.e001017.25', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/science.aaf1279'}, { 'key': '2022063000100525000_8.1.e001017.26', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/srep41926'}, { 'key': '2022063000100525000_8.1.e001017.27', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.pone.0252306', 'article-title': 'Feasibility of collecting and processing of COVID-19 convalescent ' 'plasma for treatment of COVID-19 in Uganda', 'volume': '16', 'author': 'Muttamba', 'year': '2021', 'journal-title': 'PLoS One'}, { 'key': '2022063000100525000_8.1.e001017.28', 'doi-asserted-by': 'crossref', 'unstructured': 'Muttamba W , Lusiba J , Namakula LO . Feasibility of collecting and ' 'processing of COVID-19 convalescent plasma for treatment of COVID-19 in ' 'Uganda 2020.', 'DOI': '10.1101/2020.10.29.20222067'}, { 'key': '2022063000100525000_8.1.e001017.29', 'unstructured': 'SARS-CoV-2 (COVID-19) antibody titer assay kit (Spike protein RBD) - ' 'ACROBiosystems. Available: ' 'https://www.acrobiosystems.com/P3184-SARS-CoV-2-%28COVID-19%29-antibody-titer-assay-kit-%28Spike-protein-RBD%29.html ' '[Accessed 05 Sep 2020].'}, { 'key': '2022063000100525000_8.1.e001017.30', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s11547-020-01200-3'}, { 'key': '2022063000100525000_8.1.e001017.31', 'doi-asserted-by': 'crossref', 'first-page': '1475', 'DOI': '10.1002/jmv.25961', 'article-title': 'Convalescent plasma transfusion for the treatment of COVID-19: ' 'systematic review', 'volume': '92', 'author': 'Rajendran', 'year': '2020', 'journal-title': 'J Med Virol'}, { 'key': '2022063000100525000_8.1.e001017.32', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.1004'}, { 'key': '2022063000100525000_8.1.e001017.33', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s10096-004-1271-9'}, { 'key': '2022063000100525000_8.1.e001017.34', 'doi-asserted-by': 'crossref', 'first-page': '102875', 'DOI': '10.1016/j.transci.2020.102875', 'article-title': 'Clinical efficacy of convalescent plasma for treatment of COVID-19 ' 'infections: results of a multicenter clinical study', 'volume': '59', 'author': 'Abolghasemi', 'year': '2020', 'journal-title': 'Transfus Apher Sci'}, { 'key': '2022063000100525000_8.1.e001017.35', 'doi-asserted-by': 'crossref', 'DOI': '10.3390/jcm9072268', 'article-title': 'Neutralizing antibody production in asymptomatic and mild COVID-19 ' 'patients, in comparison with pneumonic COVID-19 patients', 'volume': '9', 'author': 'Ko', 'year': '2020', 'journal-title': 'J Clin Med'}, { 'key': '2022063000100525000_8.1.e001017.36', 'doi-asserted-by': 'crossref', 'unstructured': 'Gharbharan A , Jordans CC , GeurtsvanKessel C . Convalescent plasma for ' 'COVID-19. A randomized clinical trial. Medrxiv ' '2020.doi:10.1101/2020.07.01.20139857', 'DOI': '10.1101/2020.07.01.20139857'}], 'container-title': 'BMJ Open Respiratory Research', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1136/bmjresp-2021-001017', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 6, 30]], 'date-time': '2022-06-30T07:10:34Z', 'timestamp': 1656573034000}, 'score': 1, 'resource': {'primary': {'URL': 'https://bmjopenrespres.bmj.com/lookup/doi/10.1136/bmjresp-2021-001017'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 8]]}, 'references-count': 36, 'journal-issue': { 'issue': '1', 'published-online': {'date-parts': [[2021, 8, 9]]}, 'published-print': {'date-parts': [[2021, 8]]}}, 'alternative-id': ['10.1136/bmjresp-2021-001017'], 'URL': 'http://dx.doi.org/10.1136/bmjresp-2021-001017', 'relation': {}, 'ISSN': ['2052-4439'], 'subject': ['Pulmonary and Respiratory Medicine'], 'container-title-short': 'BMJ Open Resp Res', 'published': {'date-parts': [[2021, 8]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit